Liu Xiaolin, Wang Zongyao, Lv Xiang, Tao Zhihui, Lin Liubing, Zhao Shasha, Zhang Kehui, Li Yong
Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
Sartorius Stedim (Shanghai) Trading Co., Ltd, Shanghai 201210, China.
Heliyon. 2024 Aug 2;10(15):e34968. doi: 10.1016/j.heliyon.2024.e34968. eCollection 2024 Aug 15.
The interaction between cancer cells and the tumor microenvironment is of critical importance in liver cancer. Jiedu Granule formula (JDF) has been shown to minimize the risk of recurrence and metastasis following liver cancer resection. Investigating the mechanism underlying the therapeutic effects of JDF can extend its field of application and develop novel treatment approaches.
We established a rat liver orthotopic transplantation tumor model, and recorded the prognostic effects of JDF adjuvant therapy on the recurrence and metastasis of liver cancer. Liver and lung tissues were collected for immunofluorescence staining and H&E staining, respectively. In addition, THP-1 cells were incubated with PMA and IL-4 to induce them to differentiate into M2 macrophages. CSF-1 expression was knocked down using lentivirus to determine the function of CSF-1. Liver cancer cells were cultured with a conditioned medium (CM) or co-cultured with macrophages. Cell viability was determined using the MTT assay. The levels of CSF-1, CSF-1R, E-cadherin, N-cadherin, PI3K, AKT, and cleaved caspase-3 were detected using ELISA, Western blotting and qPCR. The ability of cells to migrate was assessed using cell scratch and transwell assays. Apoptosis was evaluated using flow cytometry.
The JDF treatment decreased the risk of liver cancer metastasis after surgery and the infiltration of CD206/CD68 cells in liver cancer tissue. In cell experiments, JDF showed effects in suppressing M2 macrophages activity and downregulating the expression of CSF-1 and CSF-1R. The concentration of CSF-1 in the supernatant was also lower in the JDF-treated group. Futhermore, M2-CM was found to promote cancer cell migration and epithelial-mesenchymal transition (EMT); however, these effects were weakened after administering JDF. Knocking down endogenous CSF-1 in M2 macrophages resulted in a comparable suppression of cancer cell migration and EMT. Additionally, JDF treatment inhibited activation of the PI3K/AKT pathway, thus promoting the apoptosis of M2 macrophages.
Treatment with JDF reduced the EMT and migratory capacity of liver cancer cells, which might be attributed to the inhibition of M2 macrophage infiltration and interruption of the CSF-1/PI3K/AKT signaling pathway. This mechanism may hold significant implications for mitigating the risk of metastatic spread in the aftermath of hepatic surgery.
癌细胞与肿瘤微环境之间的相互作用在肝癌中至关重要。解毒颗粒配方(JDF)已被证明可降低肝癌切除术后复发和转移的风险。研究JDF治疗效果的潜在机制可以扩大其应用范围并开发新的治疗方法。
我们建立了大鼠肝原位移植肿瘤模型,并记录了JDF辅助治疗对肝癌复发和转移的预后影响。分别收集肝脏和肺组织进行免疫荧光染色和苏木精-伊红(H&E)染色。此外,将THP-1细胞与佛波酯(PMA)和白细胞介素-4(IL-4)孵育以诱导它们分化为M2巨噬细胞。使用慢病毒敲低集落刺激因子-1(CSF-1)的表达以确定CSF-1的功能。肝癌细胞用条件培养基(CM)培养或与巨噬细胞共培养。使用MTT法测定细胞活力。使用酶联免疫吸附测定(ELISA)、蛋白质免疫印迹法(Western blotting)和定量聚合酶链反应(qPCR)检测CSF-1、CSF-1受体(CSF-1R)、E-钙黏蛋白、N-钙黏蛋白、磷脂酰肌醇-3-激酶(PI3K)、蛋白激酶B(AKT)和裂解的半胱天冬酶-3的水平。使用细胞划痕试验和Transwell试验评估细胞迁移能力。使用流式细胞术评估细胞凋亡。
JDF治疗降低了术后肝癌转移的风险以及肝癌组织中CD206/CD68细胞的浸润。在细胞实验中,JDF显示出抑制M2巨噬细胞活性和下调CSF-1和CSF-1R表达的作用。JDF治疗组上清液中CSF-1的浓度也较低。此外,发现M2-CM可促进癌细胞迁移和上皮-间质转化(EMT);然而,给予JDF后这些作用减弱。敲低M2巨噬细胞中的内源性CSF-1导致对癌细胞迁移和EMT的类似抑制。此外,JDF治疗抑制了PI3K/AKT信号通路的激活,从而促进了M2巨噬细胞的凋亡。
JDF治疗降低了肝癌细胞的EMT和迁移能力,这可能归因于对M2巨噬细胞浸润的抑制和CSF-1/PI3K/AKT信号通路的中断。这一机制可能对降低肝切除术后转移扩散的风险具有重要意义。